SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IRWD

Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ: IRWD · Real-Time Price · USD
Healthcare · Drug Manufacturers - Specialty & Generic
$4.87+$0.02 (+0.41%)
 
Market cap
$806M
Insider Score
Analyst consensus
Market Cap$806.23M+55.6%
Revenue (ttm)$400.30M
Net Income$149.63M
EPS$0.90
Shares Out165.55M
PE Ratio5.41
Forward PE3.11
Dividendn/a
Ex-Dividend Daten/a
Volume2,824,889
Open$4.83
Previous Close$4.85
Day's Range$4.76 - $4.89
52-Week Range$2.95 - $5.78
Beta0.24
AnalystsBuy
Price Target$6.17(+26.80%)
Earnings DateNov 5, 2026

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Address
100 Summer Street, Boston, MA, 02110, United States
Market Cap
806 million
Employees
100
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$21.19M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
+0.41%
5 Days
+1.25%
1 Month
+36.80%
6 Months
+32.70%
1 Year
+55.59%

$IRWD stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IRWD holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IRWD's directors and management

Net Shares Purchased by Insiders−7M−3.5M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IRWD Estimated quarterly lobbying spending

Source: U.S. Senate LDA

IRWD Revenue by Segment

$132.25MTotal
Collaborative arrangements revenue$130.75M98.87%
Royalty$1.50M1.13%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New IRWD patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IRWD from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IRWD’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
84
News & Sentiment
38% of score
72

News check: Q3 earnings beat, revenue miss, but raised 2026 guidance driven by record LINZESS sales growth outweigh the miss.

Recent Insider Activity

Buys
0
Sells
4
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBPVirtus Biotech ETF1.72%
FDMFirst Trust Dow Jones Select MicroCap Index Fund1.20%
PEPTREX Peptide ETF0.92%
ABLSAbacus FCF Small Cap Leaders ETF0.75%
QQQSInvesco NASDAQ Future Gen 200 ETF0.65%
DSMCDistillate Small/Mid Cash Flow ETF0.57%
FSMLFranklin Small Cap Enhanced ETF0.38%
AESLHarbor AlphaEdge Small Cap Value ETF0.37%
AESBHarbor AlphaEdge Small Cap Core ETF0.37%
AESGHarbor AlphaEdge Small Cap Growth ETF0.36%
SQLVRoyce Quant Small-Cap Quality Value ETF0.31%
SFLOVictoryShares Small Cap Free Cash Flow ETF0.30%

Weight is the stock’s share of each fund’s holdings.